A 1:1 combination of cannabidiol and Δ9-tetrahydrocannabinol inhibit toll-like receptor 7- and 8-mediated inflammation in human immune cells

Eur J Pharmacol. 2025 Sep 15:1003:177878. doi: 10.1016/j.ejphar.2025.177878. Epub 2025 Jul 2.

Abstract

Cannabinoid regulation of endosomal signalling via innate immune toll-like receptors (TLRs) is understudied. Endosomal cell signalling via TLR7 and TLR8 governs cellular responses to infection with viral and bacterial single-stranded RNA. TLR7/8 activation is associated with neuroinflammation, with inappropriate activation of TLR7/8 linked to the propagation of autoimmune disease. Following activation, TLR7 and TLR8 control the cellular production of cytokines, chemokines and type I interferons (IFNs). In this study we focused on two clinically relevant plant-derived (phyto) cannabinoids, cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), given that cannabinoid-based therapeutics containing these compounds are currently available in the form of sativex® (nabiximols) and epidiolex®. The study aim was to determine the anti-inflammatory effects of CBD and THC, when delivered in isolation and in a sativex-like combination (1:1), on TLR7/8-induced inflammation in immune cells. We employed the use of CL075 (3M-002), a thiazoloquinolone derivative that acts as an agonist of both TLR7 and TLR8. Using THP-1-derived macrophages and primary peripheral blood mononuclear cells (PBMCs) from healthy control subjects, we demonstrate that TLR7/8 activation promoted the time- and concentration-dependent production of the chemokine CXCL10, cytokine TNFα and type I IFNs in both macrophages and PBMCs. TLR7/8 activation promoted nuclear factor (NF)-κB activation, p38 MAPK phosphorylation and the transcription of interferon regulator factor 7 (IRF7). We assessed the anti-inflammatory effects of CBD and THC, when delivered alone and in a 1:1 combination, on CL075-stimulated inflammatory mediator production in macrophages/PBMCs. Data presented herein indicate that CBD and THC, particularly when delivered in a 1:1 combination, can act as TLR7/8 immunomodulatory drugs to dampen inflammation in macrophages and PBMCs. This study provides evidence that phytocannabinoids target TLR7/8-induced viral signalling on endosomal compartments to control inflammation in immune cells.

Keywords: Endosome; Inflammation; Innate immunity; Phytocannabinoids; Sativex®; TLR7/8.

MeSH terms

  • Anti-Inflammatory Agents* / pharmacology
  • Cannabidiol* / pharmacology
  • Cytokines / metabolism
  • Dronabinol* / pharmacology
  • Humans
  • Inflammation* / drug therapy
  • Inflammation* / immunology
  • Inflammation* / metabolism
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / metabolism
  • Macrophages / drug effects
  • Macrophages / immunology
  • Macrophages / metabolism
  • NF-kappa B / metabolism
  • Signal Transduction / drug effects
  • Toll-Like Receptor 7* / agonists
  • Toll-Like Receptor 7* / metabolism
  • Toll-Like Receptor 8* / agonists
  • Toll-Like Receptor 8* / metabolism

Substances

  • Cannabidiol
  • Toll-Like Receptor 7
  • Toll-Like Receptor 8
  • Dronabinol
  • TLR7 protein, human
  • TLR8 protein, human
  • Anti-Inflammatory Agents
  • Cytokines
  • NF-kappa B